Mandate

Vinge advises Bufab in connection with the listing on NASDAQ OMX Stockholm

February 27, 2014

Vinge advises Bufab in connection with the listing on NASDAQ OMX Stockholm and Nordic Capital Fund V:s offering of shares in connection with the listing. Bufab is a trading company that delivers components and services to the global manufacturing industry. Bufab is a trading company that delivers components and services to the global manufacturing industry. The Company offers its customers a one-stop-shop product offering that covers sourcing, quality assurance and logistics of so called C-Parts, components such as nuts, screws and washers, according to the business model Supply Chain Partner. The Swedish language prospectus was published on 10 February 2014 and the first day of trading was 21 February 2014. The offering attracted strong interest among Swedish and international institutional investors as well as Swedish retail investors. The Offering was over-subscribed multiple times. The final offering price has been set at SEK 46 per share, corresponding to a market value of all shares issued by Bufab of MSEK 1,753.

Vinge’s team consisted of, among others, partners Charlotte Levin, Peter Bäärnhielm and Christina Kokko and associates Jonas Johansson, David Andersson, Mia Örnfeldt, Albert Wållgren and Rikard Lindahl.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025